Efficacy and safety of oral desmopressin in the treatment of primary nocturnal enuresis in Asian children

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin.

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

Children with primary monosymptomatic nocturnal enuresis, aged between 7 and 18 years, with a minimum frequency of wetting of 6 nights or more during a 2-week observation period were recruited.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, crossover and multicenter.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

The timeline in the abstract includes 2 weeks.

This was a multicentre randomized placebo-controlled double-blind cross-over study.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Asia, Deamino Arginine Vasopressin, Enuresis and Renal Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin over 2 weeks.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (Journal of paediatrics and child health), a journal based in Australia.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.